Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Prescription Dermatological Drugs Market from 2024 to 2025?
In recent years, the market size for prescription dermatological drugs has seen a robust growth. It is projected to increase from $37.77 billion in 2024 to $40.38 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. The historic growth trend has been fuelled by several factors including the increased prevalence of skin disorders, rising awareness about skin health, expansion in the number of dermatology clinics, an aging population, heightened healthcare expenditure, and increased research and development investments.
What Is the Projected Market Size of the Prescription Dermatological Drugs Market?
Expectations are high for robust growth in the prescription dermatological drugs market in the forthcoming years. The predicted market size is anticipated to reach $52.27 billion in 2029, growing at a compound annual growth rate (CAGR) of 6.7%. The projected acceleration during this forecast period is due to an upsurge in skin-related disorders, heightened consciousness about skin health, a surge in the adoption of telemedicine for dermatology consultations, growth in skin care aesthetics, improved insurance provisions for skin treatments, and a rise in the demand for custom-made medicine and precision dermatology. Major trends enumerated for this period include growth in targeted biologic therapies, utilization of gene editing for skin diseases, progression in drug transportation methods, personalized treatment approaches based on genetic profiling, usage of topical medications with superior absorption and the employment of artificial intelligence for the optimization of drug formulas and treatment schedules.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21262&type=smp
Who are the Major Competitors in the Prescription Dermatological Drugs Market Outlook?
Major companies operating in the prescription dermatological drugs market are Pfizer Inc., Johnson & Johnson, Merck KGaA, AbbVie Inc., Bayer AG, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Mylan NV, Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Zydus Cadila Health Care Limited, Leo Pharma A/S, Glenmark Pharmaceuticals Limited, Almirall S.A., DermBiont Inc.
What Is Fueling Growth in the Prescription Dermatological Drugs Market?
The surge in dermatological issues is predicted to boost the expansion of the prescription dermatological drugs market. Illnesses affecting the skin, hair, or nails, like eczema, psoriasis, and acne, are considered dermatological conditions, and they demand medical intervention for effective symptom control. This rise in dermatological conditions can be chiefly attributed to increasing exposure to environmental pollutants, shifts in lifestyle, and elevated stress levels. Prescription dermatological medications are vital in managing these conditions, offering specialized treatments that alleviate symptoms and enhance skin health over time. For example, in a study organized by Europe PubMed Central, a UK-based entity supervised by EMBL’s European Bioinformatics Institute for biomedical research studies, carried out across 27 European nations in March 2022, an estimated 43.35% of participants, translating to almost 185 million individuals, suffered from a minimum of one skin issue. Fungal infections, atopic dermatitis, and acne were the most prevalent conditions. Accordingly, the surge in dermatological issues is propelling the expansion of the prescription dermatological drugs market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21262&type=smp
Which Prescription Dermatological Drugs Market Segments Are Growing the Fastest?
The prescription dermatological drugs market covered in this report is segmented –
1) By Drug Class: Corticosteroids, Retinoids, Calcineurin Inhibitors, Antifungal Agents, Antibiotics, Other Drug Classes
2) By Indication: Acne, Psoriasis, Dermatitis, Fungal Skin Infections, Other Indications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Retinoids: Topical Retinoids, Oral Retinoids
3) By Calcineurin Inhibitors: Topical Calcineurin Inhibitors, Oral Calcineurin Inhibitors
4) By Antifungal Agents: Topical Antifungals, Oral Antifungals
5) By Antibiotics: Topical Antibiotics, Oral Antibiotics
6) By Other Drug Classes: Immunosuppressants, Phototherapy Agents
Which Industry Trends Are Shaping the Future of the Prescription Dermatological Drugs Market?
Leading corporations in the prescription dermatological drugs market are concentrating their efforts on the creation of novel treatments like prurigo nodularis. This is an attempt to meet as yet unfulfilled medical needs and provide more efficacious solutions for patients dealing with persistent and complex skin conditions. Prurigo nodularis is recognized as a long-lasting skin disorder marked by the occurrence of severely itchy, raised, and sturdy nodules or bumps on the skin. For instance, it was in September 2022 that Regeneron Pharmaceuticals Inc., an American biotech firm, collaborated with France’s Sanofi S.A., receiving approval from the U.S. Food and Drug Administration (FDA) for Dupixent (dupilumab). This stands as the singular FDA-endorsed treatment for prurigo nodularis, a chronic skin ailment notable for intensely itchy nodules. The approval was given on the basis of clinical tests that indicated significant improvement in itch intensity and skin lesions in patients who were treated with Dupixent in comparison to those given a placebo.
Access The Full Report Here:
Which Countries Are Leading the Prescription Dermatological Drugs Market?
North America was the largest region in the prescription dermatological drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prescription dermatological drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21262
This Report Delivers Insight On:
1. How big is the prescription dermatological drugs market, and how is it changing globally?
2. Who are the major companies in the prescription dermatological drugs market, and how are they performing?
3. What are the key opportunities and risks in the prescription dermatological drugs market right now?
4. Which products or customer segments are growing the most in the prescription dermatological drugs market?
5. What factors are helping or slowing down the growth of the prescription dermatological drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model